Omniab, Inc. ( (OABI) ) has released its Q2 earnings. Here is a breakdown of the information Omniab, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
OmniAb, Inc. is a biotechnology company that licenses advanced discovery research technology to pharmaceutical and biotech firms, focusing on creating and screening diverse antibody repertoires for drug development.
In its second quarter of 2025, OmniAb reported a decline in revenue compared to the previous year, with a focus on expanding its partner base and launching the xPloration Partner Access Program to enhance its technological offerings.
Key financial highlights include a revenue of $3.9 million, a decrease from $7.6 million in the same quarter of 2024, primarily due to reduced milestone and service revenues. The company reported a net loss of $15.9 million, slightly higher than the previous year’s loss. Notably, OmniAb entered into six new license agreements and highlighted the launch of its xPloration program, which leverages AI and machine learning for antibody screening.
Despite financial challenges, OmniAb’s management remains optimistic about the future, reaffirming its revenue guidance for 2025 and emphasizing the potential of its innovative technology platform and new partnerships to drive long-term growth.